Drug Profile
Chlorophenyl/piperagone
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Institute of Materia Medica
- Developer Beijing Collab Pharma
- Class Small molecules
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Rheumatoid arthritis in China (PO) (Beijing Collab Pharma pipeline, August 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China (PO)
- 07 Mar 2016 Preclinical trials in Rheumatoid arthritis in China (PO)